Lynparza (olaparib)

pCPA File Number: 22319
Negotiation Status:
Concluded with an LOI
For the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy
AstraZeneca Canada Inc.
CADTH Project Number:
pCPA Engagement Letter Issued:
Negotiation Process Concluded: